dadstimeon Posted April 1, 2006 Share Posted April 1, 2006 http://sanfrancisco.bizjournals.com/san ... rround=lfn San Francisco Business Times - 1:55 PM PST Friday Hana Biosciences Inc. said Friday it started a Phase II trial of its drug Talotrexin in patients with lung cancer. The South San Francisco company (AMEX: HBX) is testing the drug in patients with relapsed or refractory non-small cell lung cancer. The primary objective of the trial is to show an improvement in overall survival of patients. Secondary goals include safety, response rate and the length of time patients go without the disease progressing. Hana will present updated information from the trial at a conference in Atlanta in June. More than a million people around the world die from lung cancer every year. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.